Theraclone Sciences Inc, based in Seattle, WA, is a leading biotechnology company specializing in the rapid identification of rare human monoclonal antibodies that have evolved to effectively combat infections and diseases. With over a decade of experience, Theraclone Sciences has perfected its platform technology to discover these antibodies, which are then developed into safe and effective therapeutic products.
The company has successfully licensed its HIV broadly neutralizing fully-human antibodies to Gilead, who are utilizing them as part of an HIV-cure regimen. Additionally, Theraclone Sciences has licensed its platform technology to OncoResponse for use in the field of oncology, further expanding the potential applications of their groundbreaking research.
Generated from the website